Melanoma-specific CD4+ T cell receptor (CD4+ TCR)

Melanoma-specific CD4+ T cell receptors (TCRs) are specialized antigen-recognition proteins found on the surface of CD4+ helper T cells that specifically target melanoma-associated antigens or neoantigens. Unlike the more commonly studied CD8+ TCRs that recognize antigens presented by MHC class I, these receptors recognize peptides presented by Major Histocompatibility Complex (MHC) class II molecules, such as HLA-DR, HLA-DP, or HLA-DQ (Tran et al., 2014, Science). In melanoma, these TCRs often target cancer-testis antigens such as NY-ESO-1, MAGE-A3, and PRAME, or unique mutations (neoantigens) resulting from the high mutational burden of the disease (Robbins et al., 2011, J Clin Oncol). Upon binding to their cognate antigen-MHC complex, CD4+ TCRs initiate a signaling cascade that results in the production of pro-inflammatory cytokines like interferon-gamma and tumor necrosis factor, which orchestrate a broader immune response and can directly mediate tumor regression (Oh et al., 2020, Nature). Therapeutic applications involve the use of adoptive cell transfer (ACT), where patients receive T cells genetically engineered to express these high-affinity receptors to overcome immune tolerance and achieve durable clinical responses in metastatic melanoma (Morgan et al., 2013, J Immunother). These receptors are critical for providing help to CD8+ T cells and can sometimes exhibit direct cytotoxic activity against MHC class II-positive tumor cells.

Other names

Melanoma-reactive CD4+ TCRMHC class II-restricted T-cell receptorCD4+ T-cell receptorTumor-reactive CD4+ TCR

Engineered or endogenous T-cell receptors on CD4+ T cells recognize specific melanoma-associated antigens or neoantigens presented by MHC class II molecules. This recognition triggers T-cell activation, leading to the secretion of Th1 cytokines like IFN-gamma and TNF-alpha, which promote an inflammatory tumor microenvironment and can induce direct tumor cell lysis or enhance CD8+ T-cell cytotoxicity.